Comparative Evaluation of AmpliVue HSV 1+2 Assay with ELVIS Culture for Detecting Herpes Simplex Virus 1 (HSV-1) and HSV-2 in Clinical Specimens

Paul A. Granato, Brenda R. Alkins, Belinda Yen-Lieberman, Wallace H. Greene, Jessica Connolly, Blake W. Buchan, Nathan A. Ledeboer

Laboratory Alliance of Central New York, Liverpool, New York, USA; SUNY Upstate Medical University, Syracuse, New York, USA; Cleveland Clinic, Cleveland, Ohio, USA; Penn State Hershey Medical Center, Hershey, Pennsylvania, USA; The Medical College of Wisconsin, Milwaukee, Wisconsin, USA

The AmpliVue HSV 1+2 assay was compared to the ELVIS HSV ID and D³ Typing Culture System for the qualitative detection and differentiation of herpes simplex virus 1 (HSV-1) and HSV-2 DNA in 1,351 cutaneous and mucocutaneous specimens. Compared to ELVIS, AmpliVue had sensitivities of 95.7 and 97.6% for detecting HSV-1 and HSV-2, respectively. Following arbitration of discordant results by an independent molecular method, the AmpliVue assay had a resolved sensitivity and specificity of 99.2 and 99.7%, respectively, for both HSV-1 and HSV-2, whereas ELVIS had a resolved sensitivity of 87.1% for HSV-1 and 84.5% for HSV-2.

Herpes simplex virus 1 (HSV-1) and HSV-2 are responsible for a variety of human diseases, of which cutaneous and mucocutaneous infections are the most common (1–3). In the United States, the seroprevalences for HSV-1 and HSV-2 adult infections are 80 and 20%, respectively. Worldwide, these rates are much higher, particularly in underdeveloped countries (1, 4, 5). Though there is no cure for HSV infection, antiviral therapies are available that reduce the severity of symptoms, the duration of viral shedding, and the frequency of recurrence (6–9). However, the clinical diagnosis of cutaneous and mucocutaneous herpetic infections is problematic since it is neither sensitive nor specific (10). Therefore, timely and accurate diagnostic laboratory tests are necessary for instituting appropriate therapeutic management, counseling patients with primary infection, making decisions regarding intrapartum delivery, and justifying the use of long-term suppressive therapy.

A multicenter study was conducted to evaluate the performance of the AmpliVue HSV 1+2 assay (Quidel, San Diego, CA) compared to that of the ELVIS HSV ID and D³ Typing System (Quidel DHI, Athens, OH). A total of 1,351 cutaneous (skin, n = 271; penile, n = 129) and mucocutaneous (vaginal/cervical, n = 699, oral, n = 165; anorectal, n = 35; urethral, n = 18; ocular, n = 18; nasal, n = 16) specimens were prospectively collected and evaluated in this comparative study. However, 15 of these 1,351 specimens were excluded from the study analysis because 8 specimens yielded invalid AmpliVue results, 3 specimens produced bacterial contamination in the ELVIS culture system, and 4 specimens were positive in the ELVIS culture system but could not be typed according to the manufacturer’s protocol. These 15 specimens were removed from the study, leaving 1,336 specimens for comparative analyses. All specimens were collected on swabs, transported to the laboratory in viral transport medium (VTM), and stored at 4 to 8°C, and all testing was performed within 72 h of specimen receipt. The ELVIS and AmpliVue tests were performed at four different clinical laboratories that represented the investigative authors’ various geographic locations in the United States.

ELVIS culture was performed according to the package insert (11). Shell vials were screened microscopically after 24 and 48 h of incubation for the appearance of an intracellular blue color that was indicative of HSV infection. HSV isolates were typed with fluorescein-labeled monoclonal antibodies specific for HSV-1 and HSV-2. The AmpliVue assay is an FDA-cleared assay that detects and differentiates HSV-1 and HSV-2 DNA by using a helicase-dependent amplification (HDA) reaction that simultaneously amplifies an HSV-1-specific sequence and an HSV-2-specific sequence in the presence of an internal control (IC) sequence. The HSV-1 target sequence is located at the 5’ end of the UL20 and UL19 genes, while the HSV-2 target sequence is located between the UL47 and UL48 genes. The nature of the positive IC is proprietary.

The AmpliVue assay consists of three major steps: (i) specimen preparation involving a one-step dilution, (ii) isothermal HDA of target sequences specific for HSV-1 and HSV-2, and (iii) detection of the DNA amplicons by target-specific hybridization probes via a colorimetric reaction on a lateral-flow strip that is embedded in a self-contained disposable cassette to prevent amplicon contamination. Specimen preparation involves one simple dilution of 20 µl of VTM to a dilution tube containing a buffer. After mixing by inversion, 50 µl of the diluted specimen is transferred into a 0.2-ml reaction tube that contains lyophilized HDA reagents, de-
oxygenucleoside triphosphates, primers, and probes. Incubation at 64°C for 45 min results in the release of the HSV DNA and subsequent isothermal amplification of the target sequence by HSV-1- and HSV-2-specific primers. The amplified DNA is detected by a set of specific detection probes included in the reaction tube; the HSV-1 target hybridizes to two specific probes labeled with biotin (BioTEG) and digoxigenin (DIG), and the HSV-2 target hybridizes to two specific probes labeled with BioTEG and 6-carboxyfluorescein (FAM). A competitive IC is included in the reaction tube to monitor for inhibitory substances in the clinical specimens, reagent failure, or device failure. The IC target is amplified by HSV-2-specific primers and hybridizes to the biotin-labeled HSV-2 probe and the IC-specific probe labeled with 2,4-dinitrophenyl (DNP-TEG).

Detection of the amplified DNA with specific probes is achieved by using the AmpliVue cassette. The cross-contamination-proof AmpliVue cassette contains lateral-flow DNA detection strips coated with anti-DNP antibodies (C line), anti-DIG antibodies (T1 line), and anti-FAM antibodies (T2 line). HSV-1 amplicons with BioTEG- and DIG-labeled probes are captured by the anti-DIG antibodies at the T1 line, and HSV-2 amplicons with BioTEG- and FAM-labeled probes are captured by anti-FAM antibodies at the T2 line, while IC amplicons with BioTEG- and DNP-labeled probes are captured by anti-DNP antibodies at the C line. The biotin in the amplicon-probe complexes captures the streptavidin-conjugated colored particles for visualization, and a test result is a pink-to-red line that is read visually. A positive result for HSV-1 (detection of HSV-1 DNA) is reported when the T1 line is visible through the cassette detection window, while a positive result for HSV-2 (detection of HSV-2 DNA) is reported when the T2 line is visible through the detection window. A positive result for both HSV-1 and HSV-2 (detection of both HSV-1 and HSV-2 DNAs) is reported when the T1 and T2 lines are both visible through the cassette detection window. A negative result (no detection of HSV-1 or HSV-2 DNA) is reported only when the C line is displayed. The C line must always be visible to report a positive or negative HSV result. The assay result is invalid when the T1 line, T2 line, and C line are not visible. If repeat testing of an invalid specimen produced a second invalid result, the specimen was reported as invalid and no further testing was performed.

Specimens with discordant ELVIS and AmpliVue test results were sent to a reference laboratory (Quidel-DHI, Athens, OH) for arbitration analysis by alternative molecular assays, i.e., the Lyra Direct HSV 1+2/VZV assay (Quidel, San Diego, CA) and bidirectional sequence analysis (Beckman Coulter Genomics, Danvers, MA). For HSV-1, the Lyra assay targets the gene sequence responsible for glycoprotein G, while for HSV-2, the LYRA targets the gene sequence for glycoprotein G2. Any amplicons generated by the Lyra assay were analyzed by bidirectional sequencing, which provided perfect correlation with Lyra in detecting HSV-1 or HSV-2 DNA when it was present in the sample.

The performance of the AmpliVue HSV test compared to that of ELVIS culture for detecting HSV-1 in 1,351 specimens before and after discordant-result analysis is shown in Table 1. Fifteen specimens were removed from the analysis because of invalid AmpliVue results (n = 8), bacterial contamination in ELVIS culture (n = 3), or positive but untypeable HSV isolates according to the test protocol (n = 4). Thus, 1,336 specimens were available for comparative study. Compared to ELVIS as the reference method, the AmpliVue assay had a sensitivity of 95.7% and a specificity of 97.0%. Of the 42 discordant specimens, 40 were available for arbitration testing. Two specimens could not be tested because of insufficient sample volume and were removed from the analysis. As shown in Table 1, the sensitivity and specificity of the AmpliVue assay for detecting HSV-1 improved to 99.0 and 99.7%, respectively, after discordant-result resolution was obtained by the independent molecular methods. Importantly, 31 of the 34 “negative” ELVIS culture results were false negative after discordant-result resolution by molecular testing, producing a resolved ELVIS culture sensitivity of 87.1% for HSV-1.

Table 2 shows the performance of the AmpliVue HSV assay compared to that of ELVIS culture for the detection of HSV-2. With ELVIS as the reference method, the AmpliVue assay had a sensitivity of 97.6% and a specificity of 95.7% for detecting...
TABLE 2 Comparison of AmpliVue HSV 1+2 assay with ELVIS culture for detection of HSV-2 before and after discordant-result analysis

| AmpliVue HSV 1+2 assay result | No. of ELVIS culture results | % Sensitivity | % Specificity | % PPV \(b\) | % NPV \(c\) | % Prevalence | % Total agreement |
|------------------------------|-----------------------------|--------------|--------------|------------|----------|-------------|-----------------
| Before discordant-result analysis | Positive | 206 | 48 | 254 | 97.6 (94.6–99.0) | 95.7 (94.4–96.8) | 81.1 (75.8–85.4) | 99.5 (98.9–99.8) | 15.8 | 96.0 |
| Negative | 5 | 1.077 | 1.082 | 211 | 1.125 | 1.336 | 99.2 (97.1–99.8) | 99.7 (99.2–99.9) | 98.8 (96.5–99.6) | 99.8 (99.3–99.9) | 18.4 | 99.6 |

After discordant-result analysis \(d\)

| Positive | 243 | 3 | 246 | 99.2 (97.1–99.8) | 99.7 (99.2–99.9) | 98.8 (96.5–99.6) | 99.8 (99.3–99.9) | 18.4 | 99.6 |
| Negative | 2 | 1.080 | 1.082 | 245 | 1.083 | 1.328 | 99.2 (97.1–99.8) | 99.7 (99.2–99.9) | 98.8 (96.5–99.6) | 99.8 (99.3–99.9) | 18.4 | 99.6 |

\(a\) Eight of the 53 discordant specimens could not be tested because of insufficient volume. Discordant-result analysis was performed by using alternative molecular methods (Lyra HSV 1+2/VZV) and bidirectional sequencing.

\(b\) PPV, positive predictive value.

\(c\) NPV, negative predictive value.

\(d\) Each value in parentheses is the 95% confidence interval.

ACKNOWLEDGMENTS

Quidel Molecular provided materials and financial support for this study.

REFERENCES

1. Gupta R, Warren T, Wald A. 2007. Genital herpes. Lancet 370:2127–2137. http://dx.doi.org/10.1016/S0140-6736(07)61908-4.

2. Chayavichitslip P, Buckwalter JV, Krakowski AC, Friedlander SF. 2009. Herpes simplex. Pediatr Rev 30:119–129. http://dx.doi.org/10.1542/pir.30-4-119.

3. Kimberlin DW, Rousse DJ. 2004. Clinical practice. Genital herpes. N Engl J Med 350:1970–1977. http://dx.doi.org/10.1056/NEJMcp023065.

4. Xu F, Sternberg MR, Kottiri BJ, McQuillan GM, Lee FK, Nahmias AJ, Berman SM, Markowitz LE. 2006. Trends in herpes simplex virus type 1 and type 2 seroprevalence in the United States. JAMA 296:964–973. http://dx.doi.org/10.1001/jama.296.8.964.

5. Nahmias AJ, Lee FK, Beckman-Nahmias S. 1990. Sero-epidemiological and -sociological patterns of herpes simplex virus infection in the world. Scand J Infect Dis Suppl 69:19–36.

6. Roberts S. 2009. Herpes simplex virus: incidence of neonatal herpes simplex virus, maternal screening, management during pregnancy, and HIV. Curr Opin Obstet Gynecol 21:124–130. http://dx.doi.org/10.1097/GCO.0b013e3283294840.

7. Aoki FY, Tyring S, Diaz-Mitoma F, Gross G, Gao J, Hamed K. 2006. Single-day, patient-initiated famciclovir therapy for recurrent genital herpes: a randomized, double-blind, placebo-controlled trial. Clin Infect Dis 42:8–13. http://dx.doi.org/10.1086/498521.

8. Cernik G, Gallina K, Brodell RT. 2008. The treatment of herpes simplex infection: an evidence-based review. Arch Intern Med 168:1137–1144. http://dx.doi.org/10.1001/archinte.168.11.1137.

9. Whitley R. 2006. New approaches to the therapy of HSV infections. Herpes 13:53–55.

10. Workowski KA, Berman S, Centers for Disease Control and Prevention (CDC). 2010. Sexually transmitted diseases treatment guidelines, 2010. MMWR Recomm Rep 59(RR-12):1–110.

11. Anonymous. 2009. ELVIS HSV ID and D\(^3\) Typing Test System: a test system for the culture, identification and typing of Herpes simplex virus using the Enzyme Linked Virus Inducible System. Diagnostic Hybrids, Athens, OH. https://www.quidel.com/sites/default/files/product/documents/pi-050-v2en_elvis hsv_id_d3_typing_test_system_skt-elvis-xxx_v2013 apr20_1.pdf.

12. Stabell EC, O’Rourke SR, Storch GA, Olivo PD. 1993. Evaluation of a genetically engineered cell line and a histochemical beta-galactosidase assay to detect herpes simplex virus in clinical specimens. J Clin Microbiol 31:2796–2798.

13. Patel N, Kaufmann L, Baniewicz G, Forman M, Evans M, Scholl D.
1999. Confirmation of low-titer, herpes simplex virus-positive specimen results by the enzyme-linked virus-inducible system (ELVIS) using PCR and repeat testing. J Clin Microbiol 37:3986–3989.

14. Crist GA, Langer JM, Woods GL, Proctera M, Hillyard DR. 2004. Evaluation of the ELVIS plate method for the detection and typing of herpes simplex virus in clinical specimens. Diagn Microbiol Infect Dis 49:173–177. http://dx.doi.org/10.1016/j.diagmicrobio.2004.03.008.

15. Leland DS, Ginocchio CC. 2007. Role of cell culture for virus detection in the age of technology. Clin Microbiol Rev 20:49–78. http://dx.doi.org/10.1128/CMR.00002-06.

16. Wald A, Huang ML, Carrell D, Selke S, Corey L. 2003. Polymerase chain reaction for detection of herpes simplex virus (HSV) DNA on mucosal surfaces: comparison with HSV isolation in cell culture. J Infect Dis 188:1345–1351. http://dx.doi.org/10.1086/379043.